share_log

Mangoceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Mangoceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Mangoceuticals | POS AM：修改注册声明表
美股SEC公告 ·  07/26 08:03

Moomoo AI 已提取核心信息

Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
总部位于德克萨斯州的药品公司Mangoceuticals, Inc.于2024年7月26日向证券交易所(SEC)提交了一份后生效修正案，以撤销13220829股尚未出售的普通股。这些股票最初是作为之前注册声明（注册代码为No.333-278888）的一部分，登记出售并可转为500股b系列可转债股票的发行，于2024年5月9日生效。此次撤销只是针对这500股b系列可转债股票全部转换为出售者持有的2493997股普通股后的结果，日期是2024年7月25日。现在没有其它证券被撤销登记。该公司的CEO Jacob D. cohen签署了这项修正案。
总部位于德克萨斯州的药品公司Mangoceuticals, Inc.于2024年7月26日向证券交易所(SEC)提交了一份后生效修正案，以撤销13220829股尚未出售的普通股。这些股票最初是作为之前注册声明（注册代码为No.333-278888）的一部分，登记出售并可转为500股b系列可转债股票的发行，于2024年5月9日生效。此次撤销只是针对这500股b系列可转债股票全部转换为出售者持有的2493997股普通股后的结果，日期是2024年7月25日。现在没有其它证券被撤销登记。该公司的CEO Jacob D. cohen签署了这项修正案。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间